API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

FDA advisory panel recommends Galleri cancer blood test

An advisory panel to the U.S. Food and Drug Administration has voted to recommend the approval of the Galleri test, a blood test developed by biotech company GRAIL that claims to screen for over 50 types of cancer in a single draw.

While the recommendation is a significant step toward making the test widely available, experts note several limitations. Clinical trial data indicates the test struggles with early-stage cancer detection and has not yet been proven to lower cancer mortality rates or prevent advanced cancer. Reports suggest the test missed over two-thirds of cancer cases across all stages.

Additionally, despite the recommendation for approval, panel members suggested that the term “early” be removed from the product labeling describing it as an “early cancer detection test.” The FDA has not yet announced a final decision on the test.

Entities

GRAIL · Galleri · U.S. Food and Drug Administration